Takeda Puts Up to $1.3B on the Line for Keros’ Blood Cancer Anemia Drug

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a formidable challenge to Bristol Myers Squibb’s Reblozyl.